ライフサイエンスコーパス: Ad

1 Ad hoc analysis suggested that the inferior results in g

2 (Ad Hoc Percutaneous Coronary Intervention Study in Acute

3 Ad libitum access to a Western-style diet was provided a

4 Ad libitum eating from a buffet lunch was quantified imm

5 Ad libitum energy intake was assessed at lunch and dinne

6 Ad libitum food intake was assessed through the use of a

7 Ad-E1A12 increased phosphorylation of AKT1 and ribosomal

8 Ad-E1A12 infection of epithelial cancer cells displayed

9 Ad-E1A12-induced AKT1 phosphorylation was PI3K-dependent

10 Ad-GsKO mice had impaired BAT function, absent browning

11 Ad-GsKO mice had improved insulin sensitivity and glucos

12 Ad-hoc-synthesized LR/fluorescent-probe conjugates were

13 Ad-IGF-II transduction did not affect islet viability or

14 Ad-MD-2s given before HDM sensitization significantly in

15 Ad-PLIN5 in islets enhanced the augmentation of glucose-

16 Ad-S16E-PLB-transduced hES2-vCMs displayed an intermedia

17 Ad.5/3-CTV exhibited no toxicity in the brains of Syrian

18 Ad.5/3-CTV increased the survival of mice carrying GBM t

19 Ad.5/3-CTV infection of neuroblastoma cells increased AT

20 Ad.5/3-CTV promotes these effects through a unique pathw

21 Ad.EPCR treatment elicited recruitment of macrophages an

22 Ad.EPCR treatment resulted in a marked increase in tumor

23 Ad.IL-6 increased hepatic hepcidin messenger RNA levels

24 Ad/VNA-Stx treatment had no impact on diarrhea.

25 el following transduction with Ad-p27-126TS, Ad-p27 (without miR-126 target sequences), or Ad-GFP (co

26 RCSF with the adaptive mutations [HIV-1JRCSF(Ad)] functions approximately 100 times more efficiently

27 cells and forced expression of mda-7/IL-24 (Ad.mda-7) or SARI (Ad.SARI) promotes cancer-specific cel

28 Adenovirus-delivered MDA-7/IL-24 (Ad.mda-7) reduced the viability of NSCLC cells of varyin

29 n adenovirus construct that expressed MD-2s (Ad-MD-2s).

30 l cell-enriched microRNA (miRNA) miR-126-3p (Ad-p27-126TS) in an attempt to specifically reduce proli

31 tein (GFP) and the full-length human TIMP-4 (Ad-GFP-TIMP4) or GFP.

32 re injected with adenovirus specifying IL-6 (Ad.IL-6) or control adenovirus.

33 ne diammonium ion complexes (e.g., CB[7].2,6-Ad(NH3)2 and CB[7].2,6-Ad(NMe3)2) are less effective at

34 exes (e.g., CB[7].2,6-Ad(NH3)2 and CB[7].2,6-Ad(NMe3)2) are less effective at realizing the potential

35 An adenovirus expressing VEGF-A (Ad-VEGF-A(164)) replicates the tumor vasculature in mice

36 Despite the presence of these abnormalities, Ad-GsKO mice maintained normal energy balance on both st

37 -vCMs with the recombinant adenoviruses (Ad) Ad-PLB or Ad-S16E-PLB to overexpress wild-type PLB or th

38 replication incompetent GFP-expressing ad, (Ad/GFP)-ABP-PEG-HCBP1, showed a hepatoma cancer specific

39 ons of beta-cyclodextrin (betaCD)-adamantyl (Ad) host-guest and N-nitrilotriacetic acid (NTA)-histidi

40 In addition, Ad-GsKO mice maintained at thermoneutrality on a standar

41 We used an adenoviral (Ad) vector that encodes cyclin-dependent kinase inhibito

42 For adenoviral (Ad) vector-mediated gene transfer and therapy approaches

43 We sought to modify adenoviral (Ad) particles by incorporating the advantageous characte

44 Adenovirus (Ad) infection triggers a cell-specific antiviral respons

45 Adenovirus (Ad) vaccine vectors have found widespread use as vaccine

46 nt of a prototype hexon chimeric adenovirus (Ad) serotype 5 (Ad5) vector containing the hexon hyperva

47 Despite adenovirus (Ad) vector's numerous advantages for cancer gene therapy

48 en treated with a Cre-expressing adenovirus (Ad-Cre), there was a localized knockdown of Nf1 in the h

49 The human adenovirus (Ad) early protein E4-ORF3 forms a unique scaffold throug

50 The human adenovirus (Ad) serotype 5 has been tested in malaria vaccine clinic

51 DA-5 via replication-incompetent adenovirus (Ad.Mda-5) initiates multiple signaling cascades, culmina

52 lation of the model nanomedicine adenovirus (Ad) can be substantially enhanced.

53 .) injection of a nonreplicating adenovirus (Ad) vector carrying a secretory transgene of VNA-Stx (Ad

54 Our understanding of adenovirus (Ad) biology is largely extrapolated from human species C

55 help is required at the time of adenovirus (Ad) vector immunization for the development of functiona

56 ls (DCs) combined with oncolytic adenovirus (Ad) expressing antitumor cytokines induces a potent anti

57 Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer

58 esigned tumor-targeted oncolytic adenovirus (Ad-TD) to deliver non-secreting (ns) IL-12 to tumor cell

59 lication-incompetent recombinant adenovirus (Ad) vectors as candidate vaccine platforms, the mechanis

60 The adenovirus (Ad) early region 4 (E4)-ORF3 protein regulates diverse c

61 entional influenza vaccines with adenovirus (Ad) gene-based vaccines demonstrated that these viral ve

62 e Timp3, mice were injected with adenovirus (Ad)-Timp3.

63 MIN6 cells expressing PLIN5 (adenovirus [Ad]-PLIN5) and those expressing perilipin 2 (PLIN2) (Ad-

64 e that a novel chimeric serotype adenovirus, Ad.5/3-mda-7, displays greater efficacy in delivering md

65 Adenoviruses (Ad) are widely used for vaccination and gene therapy app

66 Human adenoviruses (Ad) are double-stranded DNA (dsDNA) viruses associated w

67 hES2-vCMs with the recombinant adenoviruses (Ad) Ad-PLB or Ad-S16E-PLB to overexpress wild-type PLB o

68 deficiency in mature BAT and WAT adipocytes (Ad-GsKO).

69 cted with attenuated adenoviral adiponectin (Ad-Adn) or Ad-LacZ for 2 wk.

70 enic vessel type to form in tumors and after Ad-VEGF-A(164).

71 increased by 12% relative to baseline after Ad.SCF therapy, whereas it decreased by 4.2% (P=0.004) i

72 e of a "translational block" occurring after Ad.5-mda-7 gene delivery.

73 s a reduced degree of apoptosis 1 week after Ad.SCF injection.

74 not induce an innate immune response against Ad.

75 innate and adaptive immune response against Ad. shMet-expressing oncolytic Ad (oAd; RdB/shMet) compl

76 innate and adaptive immune responses against Ad, and blood retention time was markedly prolonged by P

77 Innate immune cytokine elicitation by all Ad serotypes was abrogated by blockade of endosomal acid

78 erences expands the knowledge of alternative Ad species and may inform the selection of related Ads f

79 Notably, although Ad-gold-PEG was of similar size and surface charge to Ad

80 aCD surfaces using a linker that contains an Ad group to bind to the betaCD receptors and an NTA moie

81 Here, we report that we designed such an Ad vector (proAdDelta24.GFP), where initial Ad replicati

82 cquisition of infection by both Ad Alone and Ad/Env vaccines.

83 ts were also seen with Ad-PLB-transduced and Ad-S16E-transduced hvCMTs.

84 class I Ag presentation and impair host anti-Ad cellular activities.

85 vened an Expert Panel of members of the ASCO Ad Hoc Palliative Care Expert Panel to develop an update

86 on sarco/endoplasmic reticulum Ca2+-ATPase, Ad-PLB transduction significantly attenuated electricall

87 ion against acquisition of infection by both Ad Alone and Ad/Env vaccines.

88 These data demonstrate robust protection by Ad/Env vaccines against acquisition of neutralization-re

89 nd maintenance of CD8(+) T cell responses by Ad vector immunization is longitudinally dependent on CD

90 -driven angiogenesis, a response reversed by Ad-HO-1.

91 In most cases, Ad vaccines are engineered to be replication-defective (

92 demonstrate that pH-sensitive polymer-coated Ad complex significantly increases net positive charge u

93 In contrast, replication-competent Ad (RC-Ad) vaccines are markedly more potent but risk ca

94 n mediated by the iron dipyrrinato complex ((Ad) L)FeCl(OEt2 ) provided a model for diastereoinductio

95 In conclusion, Ad/VNA-Stx treatment is effective in protecting piglets

96 ction of an adenovirus PAI-1 cDNA construct (Ad-PAI-1) suppressed expression of uPA and collagen-I an

97 We next constructed a CRAd (Ad-kappaBF512HRE) where E1A activity was under kappaBF51

98 More common replication-defective Ad (RD-Ad) vectors with deletions of E1 avoid this risk

99 adenovirus (Onc.Ad) with a helper-dependent Ad (HDAd) that expresses a PD-L1 blocking mini-antibody

100 recombinant adenovirus expressing Ad12 E1A (Ad-E1A12) that can strongly induce apoptosis.

101 xpress a fusion protein of HPV-16 E6 and E7 (Ad.E6E7) alone or fused with p16 (Ad.E6E7p16) and also e

102 V ejection fraction was improved with either Ad-GFP-TIMP-4 or hTIMP-4exp.

103 es for EC-specific miR-126-3p at the 3' end (Ad-p27-126TS).

104 At pH6.4, GFP-expressing Ad/PEGbPHF induced significantly higher GFP expression t

105 ild type mice within the first 8 d following Ad immunization resulted in dramatically reduced inducti

106 n of p38 MAPK fails to induce SARI following Ad.mda-7 infection.

107 ibiting AIF rescued neuroblastoma cells from Ad.5/3-CTV-induced cell death, whereas pan-caspase inhib

108 Bronchoalveolar lavage fluid from Ad-MD-2s mice transferred into lungs of naive mice befor

109 encoding for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area.

110 Consequently, GRbeta-Ad mice had increased glycogen synthase kinase 3beta (GS

111 Furthermore, GRbeta-Ad mice had increased hepatic lipid accumulation and ser

112 ery of hepatic GRbeta overexpression (GRbeta-Ad) resulted in suppression of gluconeogenic genes and h

113 Furthermore, we implemented heterologous Ad/protein immunization regimens that include a single i

114 However, Ad-PLB altered neither the global transcriptome nor ICa,

115 However, Ad-PLIN5 cells had higher lipolysis than Ad-PLIN2 cells,

116 Importantly, Ad vectors have been shown to differ significantly in th

117 Importantly, Ad-PLB-transduced hES2-vCMs uniquely responded to isopro

118 Replenishing adiponectin in Ad-KO mice increased LC3-II and Beclin1 and decreased p6

119 Intriguingly, reduced adiposity in Ad-FLD mice was associated with increased oxygen consump

120 H2AX, which in turn inhibited AIF changes in Ad.5/3-CTV-infected neuroblastoma cells.

121 tumor cells, and prevents LPS development in Ad/N1ICD mice.

122 however, these changes were not observed in Ad-KO mice.

123 the loss of cell viability were "rescued" in Ad.mda-7-treated cells incubated with Bcl-x(s) siRNA.

124 like receptor 4, which has a central role in Ad pathogenesis and is known to be tightly regulated by

125 Ad vector (proAdDelta24.GFP), where initial Ad replication is silenced by a green fluorescent protei

126 At 2 and 4 weeks after injury, Ad-p27-126TS-treated animals exhibited reduced restenosi

127 To overcome these issues, Ad has been engineered physically or chemically with num

128 e in wild-type (WT) or adiponectin knockout (Ad-KO) mice with and without adiponectin replenishment.

129 al vectors to express Nor-1 in normal liver (Ad/CMV/V5-Nor-1), or reduce its level with small hairpin

130 K) on the tripodal azido complex [(BIMPN(Mes,Ad,Me))Co(II)(N3)] (1) were monitored by EPR spectroscop

131 N-migratory insertion product [(NH-BIMPN(Mes,Ad,Me))Co(II)](BPh4) (3) is isolable and was reproducibl

132 , high-valent Co nitrido species [(BIMPN(Mes,Ad,Me))Co(IV)(N)] (2).

133 Ad-poly[N-(2-hydroxypropyl)methacrylamide] (Ad-PHPMA).

134 pty vector lacking a transgene control mice, Ad-MD-2s delivery resulted in significantly less LPS-ind

135 fic targeting of the tumor microenvironment, Ad was coated with the pH-sensitive block copolymer, met

136 inistration of the fiber- and hexon-modified Ad vectors boosted the OprF-specific humoral immune resp

137 d-PEG construct was compared to non-modified Ad or conventionally stealthed Ad-poly[N-(2-hydroxypropy

138 Moreover, Ad-FLD mice exhibited increased glucose tolerance.

139 ke and transduction compared to either naked Ad/GFP or Ad/GFP-ABP.

140 apy, the intravenous administration of naked Ad still encounters unfavorable host responses, non-spec

141 gnificantly higher GFP expression than naked Ad in both coxsackie and adenovirus receptor (CAR)-posit

142 cal properties of the generated nanocomplex, Ad/PEGbPHF, were assessed.

143 Acid uptake into CCD-112-CoN and NHDF-Ad cells was slower and comparable to levels in CRC cell

144 st cells (basal water permeability) and NHDF-Ad fibroblasts (aquaporin-facilitated water permeability

145 derived CCD-112-CoN), skin fibroblasts (NHDF-Ad), and colorectal cancer (CRC) cells (HCT116, HT29) gr

146 n acid uptake, cell-to-cell coupling in NHDF-Ad and CCD-112-CoN cells was strengthened with TGFbeta1.

147 A novel Ad vector that initially infected target tumor cells in

148 insertion to iron(II) amides (Me2IPr)RFe{NR(Ad)} (R = (neo)Pe (4a), 1-nor (4b)) without evidence of

149 Adiponectin-null (Ad(-/-)) mice and wild-type littermates were exposed to

150 of Alk2 or Alk3 did not alter the ability of Ad.IL-6 injection to induce hepatic STAT3 phosphorylatio

151 PEG-HCBP1 can protect biological activity of Ad against serum, and considerably reduced both innate a

152 nt is a consequence rather than the cause of Ad-E1A12-induced apoptosis.

153 In vivo delivery of Ad-Adn markedly attenuates CCl4-induced expression of ke

154 Indeed, delivery of Ad-p27-126TS to balloon-injured arteries in rats not onl

155 Strikingly, intraperitoneal delivery of Ad-TD-nsIL-12 significantly enhanced survival of animals

156 Strikingly, intratumoral delivery of Ad.Mda-5 led to regression of preestablished prostate ca

157 mimicking phantom, the level and distance of Ad-gold-PEG transport was shown to be substantially grea

158 One i.m. dose of Ad/VNA-Stx prevented fatal central nervous system (CNS)

159 r administration, the safety and efficacy of Ad vectors are hampered by the strong hepatic tropism an

160 he host environment for the establishment of Ad replication.

161 .66, p-value </=0.05) at 72 h and/or 96 h of Ad-eIF5A-shRNA transduction.

162 ion of Nur77 by intramyocardial injection of Ad-Nur77 substantially inhibited cardiac hypertrophy and

163 Intrapleural injection of Ad.EPCR into mice with an established MPM originating fr

164 eletion normalizes the glucose metabolism of Ad/N1ICD mice, it dramatically accelerates the LPS progn

165 ced insulin resistance in skeletal muscle of Ad-KO mice.

166 age tracing confirms the adipocyte origin of Ad/N1ICD LPS.

167 ssion caused a loss-of-function phenotype of Ad-infected cell corpses that, in contrast to cells infe

168 supplementation induces redifferentiation of Ad/N1ICD adipocytes and tumor cells, and prevents LPS de

169 ontaining the hexon hypervariable regions of Ad serotype 48 (Ad48) and expressing human immunodeficie

170 hese data suggest that careful sequencing of Ad.E6E7.p16 with Ad.alphaPD1 could improve antitumor imm

171 Atomic structures of Ad provide the basis for the development of antivirals a

172 was chemically crosslinked to the surface of Ad, generating a systemically injectable hybrid system,

173 ies comparable to or even exceeding those of Ad itself.

174 n occur at a time displaced from the time of Ad vector immunization by depletion of CD4(+)T cells.

175 the degree of late endosomal trafficking of Ad vectors results in differential stimulation of late e

176 irus 14p1 (Ad14p1) is an emergent variant of Ad serotype 14 (Ad14) that has caused increased severity

177 form aberrant acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression.

178 y properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad (HDAd) that expresses a P

179 HER2.CAR T cells and coadministration of Onc.Ad in an HER2(+) prostate cancer xenograft model.

180 R T cells alone or HER2.CAR T cells plus Onc.Ad.

181 ced tumors only to volumes comparable to Onc.Ad treatment.

182 he Ad/PEGbPHF complex platform, an oncolytic Ad expressing VEGF promoter-targeting transcriptional re

183 latin-based hydrogel to co-deliver oncolytic Ad co-expressing interleukin (IL)-12 and granulocyte-mac

184 e polymer could be used to deliver oncolytic Ad safely and efficiently to treat hepatoma.

185 ponse against Ad. shMet-expressing oncolytic Ad (oAd; RdB/shMet) complexed with ABP-PEG-HCBP1 deliver

186 haracteristics of polymer modified oncolytic Ad following each strategy for cancer treatment.

187 s have been done with either naked oncolytic Ad or combination with chemotherapies.

188 imitations in systemic delivery of oncolytic Ad (oAd) and to specifically target pancreatic cancer, n

189 elatin gel-mediated co-delivery of oncolytic Ad and DCs might be a promising strategy to efficiently

190 However, the systemic injection of oncolytic Ad in clinical applications is restricted due to signifi

191 proAdDelta24.GFP, into a fully RC, oncolytic Ad (rAdDelta24) that lyses tumor cells in culture and ge

192 ttenuated adenoviral adiponectin (Ad-Adn) or Ad-LacZ for 2 wk.

193 acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression.

194 dritic cells (DC) transduced with Ad.E6E7 or Ad.E6E7p16 with or without Ad.alphaPD1 were used to acti

195 nsduction compared to either naked Ad/GFP or Ad/GFP-ABP.

196 the recombinant adenoviruses (Ad) Ad-PLB or Ad-S16E-PLB to overexpress wild-type PLB or the pseudoph

197 d-p27 (without miR-126 target sequences), or Ad-GFP (control).

198 through adenovirus-mediated overexpression (Ad-FLD) not only induces WAT lipolysis in vivo but also

199 E6 and E7 (Ad.E6E7) alone or fused with p16 (Ad.E6E7p16) and also encoding an anti-programmed death (

200 expression of HA-p50 in p50-/- cells, p50-/-(Ad-HA-p50).

201 5) and those expressing perilipin 2 (PLIN2) (Ad-PLIN2) had higher [(3)H]FA incorporation into triglyc

202 =NAd] (pyrr2 py(2-) = bis(pyrrolyl)pyridine; Ad = 1-adamantyl) confined to a cis-divacant octahedral

203 lied to switch RD Ad into fully oncolytic RC Ad for tumor therapy and is potentially applicable to a

204 for cancer, where replication-competent (RC) Ad viral gene expression is needed, E1A has been either

205 In contrast, replication-competent Ad (RC-Ad) vaccines are markedly more potent but risk causing a

206 Replication-competent adenoviral (RC-Ad) vectors generate exceptionally strong gene-based vac

207 zation of Syrian hamsters, both SC-Ad and RC-Ad expressed transgenes at levels hundreds of times high

208 Surprisingly, SC-Ad, but not RC-Ad, generated higher levels of transgene-specific antibo

209 ic recombination can be applied to switch RD Ad into fully oncolytic RC Ad for tumor therapy and is p

210 This switches the RD Ad, proAdDelta24.GFP, into a fully RC, oncolytic Ad (rAd

211 More common replication-defective Ad (RD-Ad) vectors with deletions of E1 avoid this risk but do

212 to generate the same immune responses as RD-Ad vectors.

213 otent vaccine platforms than conventional RD-Ad vectors and may have utility as "needle-free" mucosal

214 potent vectors and vaccines than current RD-Ad vectors.

215 e engineered to be replication-defective (RD-Ad) vectors.

216 els hundreds of times higher than that of RD-Ad.

217 gglutination inhibition (HAI) titers than RD-Ad in Syrian hamsters.

218 and more persistent immune responses than RD-Ad vectors in Syrian hamsters and rhesus macaques.

219 evels of transgene-specific antibody than RD-Ad, which notably climbed in serum and vaginal wash samp

220 had markedly lower influenza titers than RD-Ad-vaccinated animals after challenge with influenza A/P

221 When RD-Ad and SC-Ad were tested by single sublingual immunizati

222 clude a single immunization with recombinant Ad vectors.

223 The resulting Ad-gold-PEG construct was compared to non-modified Ad or

224 or reduce its level with small hairpin RNAs (Ad/BLOCK-iT/Nor-1(small hairpin RNA)) after partial hepa

225 xpression of mda-7/IL-24 (Ad.mda-7) or SARI (Ad.SARI) promotes cancer-specific cell death.

226 SC-Ad-vaccinated cotton rats had markedly lower influenza t

227 we engineered "single-cycle" adenovirus (SC-Ad) vectors by deleting the gene for IIIa capsid cement

228 es testing newer single-cycle adenovirus (SC-Ad) vectors that replicate transgenes to amplify protein

229 , we developed "single-cycle" adenovirus (SC-Ad) vectors.

230 When RD-Ad and SC-Ad were tested by single sublingual immunization in rhes

231 sal immunization of Syrian hamsters, both SC-Ad and RC-Ad expressed transgenes at levels hundreds of

232 blingual immunization in rhesus macaques, SC-Ad generated higher gamma interferon (IFN-gamma) respons

233 Surprisingly, SC-Ad, but not RC-Ad, generated higher levels of transgene-

234 These data suggest that SC-Ad vectors may have utility as mucosal vaccines.

235 duce equal amounts of HA antigen in vitro SC-Ad produced markedly higher HA binding and hemagglutinat

236 r a recombinant adenovirus encoding for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the inf

237 26 are being pursued as lower-seroprevalence Ad vectors but differ at the DNA level by 34%.

238 E gene expression by adenovirus SMILE shRNA (Ad-shSMILE) significantly reversed UDCA-mediated repress

239 cyte-specific activation of Notch signaling (Ad/N1ICD) develop LPS with complete penetrance.

240 protection was also observed with a similar Ad/Env vaccine against repeated, heterologous, intrarect

241 ance of differential expression of the small Ad E1B gene product.

242 Adenoviral overexpression of SMILE (Ad-SMILE) attenuated fat accumulation and lipogenic gene

243 non-modified Ad or conventionally stealthed Ad-poly[N-(2-hydroxypropyl)methacrylamide] (Ad-PHPMA).

244 r carrying a secretory transgene of VNA-Stx (Ad/VNA-Stx) protected mice challenged with Stx2 and prot

245 er, Ad-PLIN5 cells had higher lipolysis than Ad-PLIN2 cells, which increased further by 8-Br-cAMP, in

246 3)H]FA incorporation into triglycerides than Ad-GFP control, which support their roles as LD proteins

247 e greater for Ad48 than Ad5, confirming that Ad-specific nAbs in humans are primarily, but not exclus

248 Competition assays demonstrated that Ad/GFP-ABP-PEG-HCBP1-mediated transduction was specifica

249 st strategies, and we found no evidence that Ad stimulation of the cGAS/STING DNA response had an imp

250 train.IMPORTANCE We previously reported that Ad-infected human cells exhibit E1B 19K-dependent repres

251 Here we show that Ad prime, Env protein boost vaccines protect against neu

252 Here, we show that Ad serotype 5 (Ad5) traffics rapidly to the nucleus foll

253 t expression of mda-7/IL-24 We now show that Ad.5/3-CTV induces profound neuroblastoma antiproliferat

254 The Ad Hoc Disease Transmission Advisory Committee (DTAC) re

255 The Ad/N1ICD LPS resembles human dedifferentiated LPS in his

256 was reduced by approximately 50% in both the Ad-GFP-TIMP4 and hTIMP-4exp groups at these post-MI time

257 st-MI and by >100% at 21 days post-MI in the Ad-GFP only group.

258 epitope insertion into various sites of the Ad fiber to elicit epitope-specific immunity.

259 conform to our general understanding of the Ad transcriptional program.

260 We report the x-ray crystal structure of the Ad type 4 (Ad4) E3-19K of species E bound to HLA-A2 at 2

261 study also demonstrates that the dose of the Ad vectors has an impact on the memory profile and prote

262 for the usual repression and control of the Ad-triggered host innate immune response.

263 To assess the therapeutic efficacy of the Ad/PEGbPHF complex platform, an oncolytic Ad expressing

264 single, high-dose challenge study, only the Ad/Env vaccine affords significant protection against ac

265 lly with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation tim

266 Specifically, the Ad-encoded E3-19K immunomodulatory protein targets MHC c

267 iruses from this study demonstrates that the Ad/Env vaccine blocks both neutralization-sensitive and

268 EG was of similar size and surface charge to Ad-PHPMA the increase in density, resulting from the inc

269 polyethyleneglycol (PEG) and then linked to Ad via a single reduction-cleavable 5kDa PEG.

270 lial cells did not further sensitize them to Ad-E1A12-induced apoptosis, suggesting that cell detachm

271 imited mTOR signaling and sensitized them to Ad-E1A12-induced cell killing.

272 Before transformation, Ad/N1ICD adipocytes undergo dedifferentiation that leads

273 ficantly higher in pigs after SCF treatment (Ad.SCF, 55.5+/-11.6 mm Hg versus Ad.beta-gal, 31.6+/-12.

274 As in tumors, Ad-VEGF-A(164) strikingly increased endothelial nitric o

275 In in vivo studies 0.1% of an unmodified Ad dose was shown to accumulate in tumours, whereas over

276 Epithelial cancer cells upon Ad-E1A12-induced detachment could not sustain AKT activa

277 nnate immune stimulation elicited by various Ad serotypes.

278 treatment (Ad.SCF, 55.5+/-11.6 mm Hg versus Ad.beta-gal, 31.6+/-12.6 mm Hg, P=0.005), indicating enh

279 eater extent than did a nonreplicative virus Ad.5/3-mda-7.

280 a tropism-modified cancer terminator virus (Ad.5/3-CTV), which selectively replicates in cancer cell

281 In vitro, Ad-p27-126TS protected the ability of ECs to proliferate

282 al tissues; however, this did not occur when Ad-FLD mice were fed a high-fat diet.

283 These data suggest a mechanism by which Ad vectors from various serotypes differentially trigger

284 be substantially greater than achieved with Ad-PHPMA.

285 he ICG fluorescence signal was analyzed with Ad Hoc imaging software (VR-RENDER), which provides a di

286 cacy in delivering mda-7/IL-24 compared with Ad.5-mda-7, although overall translation of the protein

287 p16-transduced DC (DC.E6E7p16) compared with Ad.E6E7 (DC.E6E7), a result that may be due to an effect

288 of CTL were increased after incubation with Ad.E6E7p16-transduced DC (DC.E6E7p16) compared with Ad.E

289 ytes from Sox9(flox/flox) mice infected with Ad-CMV-Cre.

290 that careful sequencing of Ad.E6E7.p16 with Ad.alphaPD1 could improve antitumor immunity against HPV

291 ionally, similar results were also seen with Ad-PLB-transduced and Ad-S16E-transduced hvCMTs.

292 derived dendritic cells (DC) transduced with Ad.E6E7 or Ad.E6E7p16 with or without Ad.alphaPD1 were u

293 oon injury model following transduction with Ad-p27-126TS, Ad-p27 (without miR-126 target sequences),

294 ts, which were reversed by transduction with Ad-PAI-1.

295 demonstrated by successful transduction with Ad.GFP.

296 overed from the tumours of mice treated with Ad-gold-PEG and ultrasound.

297 lary density compared with pigs treated with Ad.beta-gal was found at 3 months and suggests an angiog

298 eased by 4.2% (P=0.004) in pigs treated with Ad.beta-gal.

299 e effects, in contrast to the treatment with Ad-TD expressing unmodified IL-12.

300 d with Ad.E6E7 or Ad.E6E7p16 with or without Ad.alphaPD1 were used to activate autologous CD8 CTL in